Health Canada
Symbol of the Government of Canada
Skip to content | Skip to institutional links

Common menu bar links

Home > First Nations & Inuit Health > Reports & Publications > Non-Insured Health Benefits

Institutional links

First Nations & Inuit Health

Updates to the Drug Benefit List - Spring 2010

Warning This content was archived on June 24, 2013.

Archived Content

Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

Portable Document Format(PDF Version - 316 K)

The Non-Insured Health Benefits (NIHB) Program provides supplementary health benefits, including prescription and non-prescription drugs, for registered First Nations and recognized Inuit throughout Canada. Visit our Web Site at: www.healthcanada.gc.ca/nihb/

Benefit Definitions

Open Benefits
Open benefits are the drugs listed in the NIHB Drug Benefit List (DBL) which do not have established criteria or prior approval requirements.
Limited Use Benefits
Limited use drugs are those that have been found to be effective in specific circumstances, or which have quantity and frequency limitations. For drugs in this category, specific criteria must be met to be eligible for coverage.
Not Added To Formulary
Drugs not added to formulary are those which are not listed in the NIHB DBL after review by the national Common Drug Review (CDR) process and/or the Federal Pharmacy and Therapeutics Committee (FP&T). These drugs will not be added to the NIHB drug list because published evidence does not support the clinical value or cost of the drug relative to existing therapies. Coverage may be considered in special circumstances upon receipt of a completed "Exception Drugs Request Form" from the attending licensed practitioner. These requests are reviewed on a case by case basis.
Exclusions
Certain drug therapies for particular conditions fall outside the NIHB Program's mandate and will not be provided as benefits (e.g., cosmetic and anti-obesity drugs). As well, certain drugs will be excluded from the NIHB Program as recommended by the CDR and the FP&T because published evidence does not support the clinical value, safety or cost of the drug relative to existing therapies, or there is insufficient clinical evidence to support coverage.

Note: The appeal process and the emergency supply policy does not apply to excluded drugs.

DIN (Drug Identification Number)
MFR (Three letter identification code assigned to manufacturer name)
ST (Short-term Dispensing Policy Drug)

Top of Page

Additions to the Drug Benefit List

Open Benefits

Single-Source Drug Products
DIN MFR Brand Name Effective Date
02283700 PMS STPRAXIS ASA EC 81MG TABLET 12-02-2010
02324997 ALL LUMIGAN RC 0.01% OPHTHALMIC SOLUTION 26-02-2010
02331624 ALC AZARGA 1%/0.5% OPHTHALMIC SOLUTION 08-03-2010
80006877 JAP WAMPOLE MINERAL CALCIUM ORAL LIQUID 03-03-2010
80015351 PHA STPRIVA CAL D FORTE TABLET 22-02-2010
02239090 AZE STATACAND 4MG TABLET 10-03-2010
02332922 AZE STATACAND PLUS 32MG/12.5MG TABLET 12-03-2010
02332957 AZE STATACAND PLUS 32MG/25MG TABLET 10-03-2010
02200864 ALC CILOXAN 0.3% OPHTHALMIC OINTMENT 08-03-2010
02317966 ODN PURG-ODAN ORAL LIQUID 06-04-2010
02043394 WAY PREMARIN 0.3MG TABLET 22-04-2010
02043408 WAY PREMARIN 0.625 MG TABLET 22-04-2010
02043424 WAY PREMARIN 1.25MG TABLET 22-04-2010
02126559 AZE STIMDUR 60 MG TABLET 03-03-2010
02337835 NOV STSTALEVO 125/31.25/200MG TABLET 08-03-2010
02337827 NOV STSTALEVO 75/18.75/200MG TABLET 05-03-2010
80011134 WYE STCENTRUM JUNIOR COMPLETE TABLET 16-02-2010
02321653 SEV STCOVERSYL PLUS HD 8MG/2.5MG TABLET 26-03-2010
02317680 PED LAX-A-DAY 1G/G POWDER 06-04-2010
Multi-Source Drug Products
DIN MFR Brand Name Effective Date
02326841 DOM STDOM-AMLODIPINE 10MG TABLET 19-03-2010
02326825 DOM STDOM-AMLODIPINE 2.5MG TABLET 06-04-2010
02326833 DOM STDOM-AMLODIPINE 5MG TABLET 19-03-2010
02280124 PFI STGD-AMLODIPINE 2.5MG TABLET 06-04-2010
02326760 PMI STPHL-AMLODIPINE 2.5MG TABLET 06-04-2010
02295148 PMS STPMS-AMLODIPINE 2.5MG TABLET 06-04-2010
02331489 RIV STRIVA-AMLODIPINE 2.5MG TABLET 06-04-2010
02330474 SDZ STSANDOZ-AMLODIPINE 2.5MG TABLET 06-04-2010
02326817 ZYM STZYM-AMLODIPINE 10MG TABLET 07-04-2010
02326795 ZYM STZYM-AMLODIPINE 2.5MG TABLET 07-04-2010
02326809 ZYM STZYM-AMLODIPINE 5MG TABLET 07-04-2010
80003919 BMI STBIOCAL-D FORTE 500MG/400IU TABLET 12-02-2010
02329204 RBY RAN-CEFPROZIL 125MG/5ML ORAL LIQUID 06-04-2010
02315955 PED ALLERGY RELIEF ES (CETIRIZINE) 10MG TABLET 19-03-2010
02326086 PDL STDOCUSATE SODIUM 100MG  CAPSULE 18-03-2010
02330601 NOP STNOVO-ENALAPRIL 40MG TABLET 26-03-2010
02332566 RBY STFOSINOPRIL 10MG TABLET 06-04-2010
02332574 RBY STFOSINOPRIL 20MG TABLET 06-04-2010
02331004 JAP STJAMP-FOSINOPRIL 10MG TABLET 12-02-2010
02331012 JAP STJAMP-FOSINOPRIL 20MG TABLET 12-02-2010
02294524 RBY STRAN-FOSINOPRIL 10MG TABLET 06-04-2010
02294532 RBY STRAN-FOSINOPRIL 20MG TABLET 06-04-2010
02310465 PDL PRO-GABAPENTIN 400MG  CAPSULE 11-03-2010
02311321 PDL STPRO-ISMN 60MG TABLET 03-03-2010
02272830 APX STAPO-ISMN 60MG SR TABLET 03-03-2010
02301288 PMS STPMS-ISMN 60MG ER TABLET 03-03-2010
02309114 PMS PMS-LETROZOLE 2.5MG TABLET 17-05-2010
02344815 SDZ SANDOZ-LETROZOLE 2.5MG TABLET 17-05-2010
02281732 MEL MIRTAZAPINE 15MG TABLET 19-03-2010
02314290 NOP NOVO-NARATRIPTAN 1MG TABLET 12-02-2010
02314304 NOP NOVO-NARATRIPTAN 2.5MG TABLET 12-02-2010
02322323 SDZ SANDOZ NARATRIPTAN 2.5MG TABLET 12-02-2010
02349167 MYL STMYLAN-NIFEDIPINE ER 30MG TABLET 18-05-2010
09991054 WIL POLYETHYLENE GLYCOL 3350 POWDER 06-04-2010
09991007 WIL POLYETHYLENE GLYCOL POWDER 06-04-2010
02330954 JAP STJAMP-PRAVASTATIN 10MG TABLET 12-02-2010
02330962 JAP STJAMP-PRAVASTATIN 20MG TABLET 12-02-2010
02330970 JAP STJAMP-PRAVASTATIN 40MG TABLET 12-02-2010
80005770 PMT STPRENATAL & POSTPARTUM VITAMIN TABLET 19-03-2010
02299062 PMI PHL-QUETIAPINE 100MG TABLET 06-04-2010
02299089 PMI PHL-QUETIAPINE 200MG TABLET 06-04-2010
02299054 PMI PHL-QUETIAPINE 25MG TABLET 06-04-2010
02299097 PMI PHL-QUETIAPINE 300MG TABLET 06-04-2010
02331101 JAP STJAMP-RAMIPRIL 1.25MG  CAPSULE 12-02-2010
02331144 JAP STJAMP-RAMIPRIL 10MG  CAPSULE 12-02-2010
02331128 JAP STJAMP-RAMIPRIL 2.5MG  CAPSULE 12-02-2010
02331136 JAP STJAMP-RAMIPRIL 5MG  CAPSULE 12-02-2010
02295369 PMS STPMS-RAMIPRIL 1.25MG  CAPSULE 19-03-2010
02247919 PMS STPMS-RAMIPRIL 10MG  CAPSULE 19-03-2010
02247917 PMS STPMS-RAMIPRIL 2.5MG  CAPSULE 19-03-2010
02247918 PMS STPMS-RAMIPRIL 5MG  CAPSULE 19-03-2010
02328305 RBY RBX-RISPERIDONE 0.25MG TABLET 12-02-2010
02328313 RBY RBX-RISPERIDONE 0.5MG TABLET 12-02-2010
02328321 RBY RBX-RISPERIDONE 1MG TABLET 12-02-2010
02328348 RBY RBX-RISPERIDONE 2MG TABLET 12-02-2010
02328364 RBY RBX-RISPERIDONE 3MG TABLET 12-02-2010
02328372 RBY RBX-RISPERIDONE 4MG TABLET 12-02-2010
02337746 APX STAPO-ROPINIROLE 0.25MG TABLET 12-02-2010
02337762 APX STAPO-ROPINIROLE 1MG TABLET 12-02-2010
02337770 APX STAPO-ROPINIROLE 2MG TABLET 12-02-2010
02337800 APX STAPO-ROPINIROLE 5MG TABLET 12-02-2010
02326450 NOP NOVO-SALBUTAMOL HFA 100MCG INHALER 10-02-2010
02303779 ZYM ZYM-SERTALINE 25MG CAPSULE 17-05-2010
02303817 ZYM ZYM-SERTALINE 100MG CAPSULE 17-05-2010
02303809 ZYM ZYM-SERTALINE 50MG CAPSULE 17-05-2010
02322498 PMS PMS-TESTOSTERONE 40MG CAPSULE 10-02-2010
02331705 APX APO-VENLAFAXINE XR 150MG CAPSULE 17-05-2010
02331683 APX APO-VENLAFAXINE XR 37.5MG CAPSULE 17-05-2010
02331691 APX APO-VENLAFAXINE XR 75MG CAPSULES 17-05-2010
80003575 PMT STVITAMIN B12 MCG TABLET 17-05-2010
Top of Page

New Limited Use Benefits

Single-Source Drug Products
DIN MFR Brand Name Effective Date
02252716 ALC CIPRODEX OTIC SOLUTION 01-03-2010

Limited use benefit.

  1. for children 16 years old and under  (prior approval not required)
  2. for acute otitis media with otorrhea through tympanostomy tubes who require treatment
  3. for acute otitis externa in the presence of tympanostomy tube or known perforation of the tympanic membrane
Single-Source Drug Products
DIN MFR Brand Name Effective Date
02296489 AST ADVAGRAF 5MG ER CAPSULE 08-03-2010
02296470 AST ADVAGRAF 1MG ER CAPSULE 08-03-2010
02296462 AST ADVAGRAF 0.5MG ER  CAPSULE 02-03-2010

Limited use benefit (prior approval required).

For transplant therapy.

Single-Source Drug Products
DIN MFR Brand Name Effective Date
02324776 CER SIMPONI 50MG/.5ML PRE-FILLED INJECTION 01-06-2010
02324784 CER SIMPONI 50MG/0.5ML AUTO INJECTION 01-06-2010

Limited use benefit (prior approval required).

Criteria for initial one year coverage for a MAXIMUM dose of 50mg every month for RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS:

  1. Prescribed by a rheumatologist, AND
  2. Patient has had a tuberculin skin test performed AND
  3. For the treatment of severely active RHEUMATOID ARTHRITIS:
    • - Patient is refractory to methotrexate weekly parenteral (SC or IM) at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks
    • PLUS a minimum of two of the following:
    • - leflunomide: 20mg daily for 10 weeks OR
    • - gold: weekly injections for 20 weeks OR
    • - cyclosporine: 2-5 mg/kg/day for 12 weeks OR
    • - azathioprine: 2-3 mg/kg/day for 3 months OR
    • - sulfasalazine at least 2g daily for 3 months
    • PLUS one of the following combinations:
    • - methotrexate with cyclosporine (minimum 4 month trial on both) OR
    • - methotrexate with hydroxychloroquine and sulfasalazine (minimum 4 month trial on triple therapy) OR
    • - methotrexate with gold (minimum 12 week trial) OR
    • - in patients who are intolerant or who have contraindication to methotrexate therapy, or are refractory to a combination of at least 2 DMARDS OR
  4. For the treatment of moderate to severe PSORIATIC ARTHRITIS with at least two of the following:
    • - five or more swollen joints
    • - if less than five swollen joints, at least one joint proximal to, or including wrist or ankle
    • - more than one joint with erosion on imaging study
    • - dactylitis of two or more digits
    • - tenosynovitis refractory to oral NSAIDs and steroid injections
    • - enthesitis refractory to oral NSAIDs and steroid injections (not required for Achilles tendon)
    • - inflammatory spinal symptoms refractory to two NSAIDs (minimum four weeks trial each) and has a BASDAI greater than 4 - daily use of corticosteroids
    • - use of opioids > 12 hours per day for pain resulting from inflammation
    • Patient is refractory to:
    • - NSAIDs and
    • - methotrexate weekly parenteral (SC or IM) at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks PLUS a minimum of one of the following:
    • - leflunomide: 20mg daily for 10 weeks OR
    • - gold: weekly injections for 20 weeks OR
    • - cyclosporine: 2-5 mg/kg/day for 12 weeks OR
    • - sulfasalazine at least 2g daily for 3 months OR
  5. For the treatment of ANKYLOSING SPONDYLITIS when the following criteria are met:
    • - BASDAI > 4 AND
    • - patient is refractory to a three month trial of at least 3 NSAIDs at maximum tolerated dose AND for peripheral joint involvement, patient is refractory to weekly parenteral (SC or IM) at 20mg or greater (15mg or greater if patient is >65 years of age) for more than 8 weeks AND sulfasalazine 2g/day for four months.

NOTE: For axial involvement, patient does not need to be tried on methotrexate or sulfasalazine.

Top of Page
Multi-Source Drug Products
DIN MFR Brand Name Effective Date
02261766 SDZ SANDOZ-CALCITONIN 200U NASAL SPRAY 24-02-2010

Limited use benefit (prior approval required).

For treatment of patients with postmenopausal osteoporosis who have failed therapy, are intolerant to, or who have contraindications to both bisphosphonates and raloxifene.

Multi-Source Drug Products
DIN MFR Brand Name Effective Date
02330105 RBY RAN-FENTANYL MATRIX PATCH 12 25-02-2010
02330113 RBY RAN-FENTANYL MATRIX PATCH 25 26-02-2010
02330121 RBY RAN-FENTANYL MATRIX PATCH 50 26-02-2010
02330148 RBY RAN-FENTANYL MATRIX PATCH 75 26-02-2010
02330156 RBY RAN-FENTANYL MATRIX PATCH 100 26-02-2010

Limited use benefit (prior approval required).

For the management of chronic pain in patients who are unresponsive or intolerant to at least one long-acting oral product, such as morphine, hydromorphone and oxycodone, despite appropriate dose titration and adjunctive therapy including laxatives and antiemetics.

Multi-Source Drug Products
DIN MFR Brand Name Effective Date
02348500 NOV STNOVO-FINASTERIDE 5MG TABLET 15-05-2010
02322579 SDZ STSANDOZ-FINASTERIDE 5MG TABLET 10-05-2010
02316905 RAT STRATIO-FINASTERIDE 5MG TABLET 18-05-2010
02310112 PMS STPMS-FINASTERIDE 5MG TABLET 18-05-2010

Limited use benefit (prior approval required).

  1. for treatment of Benign Prostatic Hyperplasia (BPH) in patients who do not tolerate or have not responded to an alpha- adrenergic blocker OR
  2. for use in combination therapy when monotherapy with an alpha-blocker is not sufficient.
Multi-Source Drug Products
DIN MFR Brand Name Effective Date
02307634 DOM STDOM-PIOGLITAZONE 15MG TABLET 19-03-2010
02307642 DOM STDOM-PIOGLITAZONE 30MG TABLET 19-03-2010
02307650 DOM STDOM-PIOGLITAZONE 45MG TABLET 19-03-2010

Limited use benefit (prior approval required).

For treatment of type 2 diabetic patients who are not adequately controlled by or are intolerant to metformin and sulfonylureas or for whom these products are contraindicated.

Multi-Source Drug Products
DIN MFR Brand Name Effective Date
02298376 NOP STNOVO-RISEDRONATE 5MG TABLET 22-03-2010
02298384 NOP STNOVO-RISEDRONATE 30MG TABLET 22-03-2010
02298392 NOP STNOVO-RISEDRONATE 35MG TABLET 22-03-2010

Limited use benefit (prior approval required.)

  1. for the treatment of Paget's disease OR
  2. for the treatment of osteoporosis in patients who are 60 years of age or over OR
  3. for the treatment of osteoporosis in patients under 60 who have documented hip, vertebral or other fractures OR
  4. for the treatment of osteoporosis in patients under 60 with no evidence of fracture but who have a high (>20%) 10-year fracture risk OR
  5. for the treatment of osteoporosis in patients under 60 with moderate 10-year fracture risk AND use of systemic glucocorticoid therapy > 3 months
Top of Page

Not Added To Formulary

The following drugs will not be added to the NIHB Drug Benefit List:
DIN MFR Brand Name
02319012 LEO XAMIOL .5MG/50MC GEL (CALCIPOTRIOL/BETAMETHASONE)

Major Changes

Electronic Drug Submission Process

Please be advised that all submissions for drug products, to be reviewed for inclusion on the NIHB Drug Benefit List, must be sent to the NIHB Program electronically. Please send all drug submissions to the following email address:
NIHB.Drug.Submissions@hc-sc.gc.ca

Only one (1) copy of the submission is required. Receipt of submission will be acknowledged electronically.

Auto Approval Items

The ESI claims adjudication system now allows for Auto-Approval of selected items requiring Prior Approval (PA). The system verifies pre-requisite drug therapy as identified in the NIHB Drug Benefit List for Limited Use Criteria.

The following items are eligible for Auto Approval through the NIHB Program:

Ezetimibe (Ezetrol®)
Dutasteride (Avodart®)
Pioglitazone (Actos® and generics)
Minocycline (Minocin® and generics)
Finasteride (Proscar® and generics

Notification of Changes

Manufacturers are required to notify the NIHB Program of any significant change to listed drug products. Significant changes include changes in DIN, product name, manufacturer or distributor, indication, product monograph, packaging, formulation, manufacturing specifications or discontinuation of a product. Notification of changes should be provided electronically to NIHB.Drug.Submissions@hc-sc.gc.ca

Proton Pump Inhibitors Listing Change

Effective July 5, 2010, the NIHB Program will list the following Proton Pump Inhibitors (PPIs) as limited use benefits with quantity and frequency limits (prior approval not required). Prior approval is not required unless the quantity limit is exceeded. A maximum of 400 doses of PPIs every 180 days will be permitted. This quantity limit will begin on the date of the client's first claim for a PPI.

The following PPI's will become limited use, prior approval not required:

Losec® 10mg capsules, including generics
Losec® 20mg capsules, including generics
Losec® 20mg tablets, including generics
Pariet® 10mg tablets, including generics
Pariet® 20mg tablets, including generics
Pantoloc® 40mg tablets, including generics
Prevacid® 15mg capsules, including generics
Prevacid® 30mg capsules, including generics

The following PPIs will remain limited use, prior approval required and are subject to the quantity limit:

Prevacid® Fastabs 15mg tablets
Prevacid® Fastabs 30mg tablets
Tecta® 40mg tablets
Losec® 10mg tablets, including generics

The following PPIs will remain exceptions and are subject to the quantity limit:

Losec® Mups 10mg tablets
Losec® Mups 20mg tablets

Top of Page

Antiviral and Antibiotic Listing Change

As a result of special circumstances arising during the recent H1N1 pandemic, the coverage status of oseltamivir (Tamiflu®), zanamivir (Relenza®), moxifloxacin (Avelox®) and levofloxacin (Levaquin® and generics) was changed from exception to open benefit status. Effective July 5, 2010, these medications will be returned to exception status. Coverage of these medications may be requested on an exceptional basis by contacting the NIHB Drug Exception Center at 1-800-580-0950.

Levofloxacin (Levaquin® and generics) will continue to be available as open benefit in the 250mg and 500mg strength only for a maximum of 14 days without prior approval.

Updated Generic Submission Requirements

Please review the following updated NIHB generic submission requirements:

Letter of authorization: The manufacturer will provide a letter authorizing the NIHB Program to gain access to all information with respect to the product in the procession of the Health Canada or of the government of any province or territory in Canada, Patented Medicine Prices Review Board (PMPRB) or Canadian Agency for Drugs and Technologies in Health (CADTH).

Justification for Consideration of Listing: The manufacturer will provide a statement indicating the rationale and evidence to justify the provision of the new generic product.

General Information: Additional information should include:

  • - Evidence of approval by Health Canada, such as a Notice of Compliance (NOC) and Drug Identification Number (DIN) and
  • - Two therapeutic classifications:
    1. American Hospital Formulary Service (AHFS) Pharmacologic -- Therapeutic Classification and;
    2. The World Health Organization's Anatomical Therapeutic Chemical (ATC) classification.

Pricing and Marketing Information: The manufacturer will submit current price information for the drug product.

** Please send all generic drug submissions to the following email address NIHB.Drug.Submissions@hc-sc.gc.ca Only one (1) copy of the submission is required. Receipt of submission will be acknowledged electronically **

Criteria Change

Effective June 2010, there will be a change in coverage criteria for Fosamax, Fosavance, Actonel and all equivalent generics. Limited use benefit (prior approval required.)

  1. for the treatment of Paget's disease OR
  2. for the treatment of osteoporosis in patients who are 60 years of age or over OR
  3. for the treatment of osteoporosis in patients under 60 who have documented hip, vertebral or other fractures OR
  4. for the treatment of osteoporosis in patients under 60 with no evidence of fracture but who have a high (>20%) 10-year fracture risk OR
  5. for the treatment of osteoporosis in patients under 60 with moderate 10-year fracture risk AND use of systemic glucocorticoid therapy > 3 months
Top of Page

Additions to the Short-Term Dispensing Policy Drug List

DIN Brand Name
02272830 APO-ISMN 60MG SR TABLET
02337746 APO-ROPINIROLE 0.25MG TABLET
02337762 APO-ROPINIROLE 1MG TABLET
02337770 APO-ROPINIROLE 2MG TABLET
02337800 APO-ROPINIROLE 5MG TABLET
02239090 ATACAND 4MG TABLET
02332922 ATACAND PLUS 32MG/12.5MG TABLET
02332957 ATACAND PLUS 32MG/25MG TABLET
80003919 BIOCAL-D FORTE 500MG/400IU TABLET
80011134 CENTRUM JUNIOR COMPLETE TABLET
02321653 COVERSYL PLUS HD 8MG/2.5MG TABLET
02326086 DOCUSATE SODIUM 100MG CAPSULE
02326841 DOM-AMLODIPINE 10MG TABLET
02326825 DOM-AMLODIPINE 2.5MG TABLET
02326833 DOM-AMLODIPINE 5MG TABLET
02307634 DOM-PIOGLITAZONE 15MG TABLET
02307642 DOM-PIOGLITAZONE 30MG TABLET
02307650 DOM-PIOGLITAZONE 45MG TABLET
02332566 FOSINOPRIL 10MG TABLET
02332574 FOSINOPRIL 20MG TABLET
02280124 GD-AMLODIPINE 2.5MG TABLET
02126559 IMDUR 60MG TABLET

DIN Brand Name
02331004 JAMP-FOSINOPRIL 10MG TABLET
02331012 JAMP-FOSINOPRIL 20MG TABLET
02330954 JAMP-PRAVASTATIN 10MG TABLET
02330962 JAMP-PRAVASTATIN 20MG TABLET
02330970 JAMP-PRAVASTATIN 40MG TABLET
02331101 JAMP-RAMIPRIL 1.25MG CAPSULE
02331144 JAMP-RAMIPRIL 10MG CAPSULE
02331128 JAMP-RAMIPRIL 2.5MG CAPSULE
02331136 JAMP-RAMIPRIL 5MG CAPSULE
02349167 MYLAN-NIFEDIPINE ER 30MG TABLET
02330601 NOVO-ENALAPRIL 40MG TABLET
02348500 NOVO-FINASTERIDE 5MG TABLET
02298384 NOVO-RISEDRONATE 30MG TABLET
02298392 NOVO-RISEDRONATE 35MG TABLET
02298376 NOVO-RISEDRONATE 5MG TABLET
02326760 PHL-AMLODIPINE 2.5MG TABLET
02295148 PMS-AMLODIPINE 2.5MG TABLET
02310112 PMS-FINASTERIDE 5MG TABLET
02301288 PMS-ISMN 60MG ER TABLET
02295369 PMS-RAMIPRIL 1.25MG  CAPSULE
02247919 PMS-RAMIPRIL 10MG  CAPSULE
02247917 PMS-RAMIPRIL 2.5MG  CAPSULE
02247918 PMS-RAMIPRIL 5MG  CAPSULE
02283700 PRAXIS ASA EC 81MG TABLET
80005770 PRENATAL & POSTPARTUM VITAMIN TABLET
80015351 PRIVA CAL D FORTE TABLET
02311321 PRO-ISMN 60MG TABLET
02294524 RAN-FOSINOPRIL 10MG TABLET
02294532 RAN-FOSINOPRIL 20MG TABLET
02316905 RATIO-FINASTERIDE 5MG TABLET
02331489 RIVA-AMLODIPINE 2.5MG TABLET
02330474 SANDOZ-AMLODIPINE 2.5MG TABLET
02322579 SANDOZ-FINASTERIDE 5MG TABLET
02337835 STALEVO 125/31.25/200MG TABLET
02337827 STALEVO 75/18.75/200MG TABLET
80003575 VITAMIN B12 MCG TABLET
02326817 ZYM-AMLODIPINE 10MG TABLET
02326795 ZYM-AMLODIPINE 2.5MG TABLET
02326809 ZYM-AMLODIPINE 5MG TABLET
Date Modified: 2010-06-17

Top of Page
Important Notices